On Nov 22, major Wall Street analysts update their ratings for $Kura Oncology (KURA.US)$, with price targets ranging from $18 to $34.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and adjusts the target price from $35 to $29.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $32.
Jefferies analyst Roger Song maintains with a buy rating, and adjusts the target price from $32 to $28.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
Mizuho Securities analyst Salim Syed maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Kura Oncology (KURA.US)$'s main analysts recently are as follows:
Kura Oncology has entered a significant development and commercialization agreement with a major partner for its prime project, ziftomenib. The deal, which includes a substantial upfront payment alongside notable near-term milestones, provides Kura with a solid financial foundation to pursue pivotal frontline development. This strategic partnership allows for an extensive and aggressive development plan for ziftomenib, notably in the treatment of acute myeloid leukemia, at a critical period to maximize its commercial potential. Additionally, this agreement mitigates financial risks associated with the company's stock in the short to medium term, while preserving considerable value.
Following Kura Oncology's announcement of a global strategic alliance with Kyowa Kirin for the development and commercialization of ziftomenib, an oral menin inhibitor aimed at treating acute myeloid leukemia and other hematologic malignancies, analysts interpret this deal as strategically advantageous. It provides essential capital to expedite Kura's AML franchise and potentially positions ziftomenib as a leading treatment in its class. Despite an anticipated near-term reduction in the stock's M&A premium, the deal is seen to enhance the company's fundamental value through a strengthened balance sheet and fully funded development in key AML markets.
Here are the latest investment ratings and price targets for $Kura Oncology (KURA.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
